Novartis plans to build a new radioligand therapy manufacturing facility in Denton, Texas, adding to the company's expanding U.S. production network for advanced cancer treatments. The project calls for a purpose-built, 46,000-square-foot plant dedicated to radioligand therapy, a modality that uses targeted radiation to deliver treatment directly to cancer cells throughout the body.
The facility in Denton will be the fifth radioligand therapy manufacturing site Novartis has established in the United States and will serve as the company's first manufacturing operation in Texas. The company describes the development as part of its broader $23 billion investment program in the U.S., signaling a continued buildout of specialized production capacity to support its oncology portfolio.
Denton officials report that the cost of the new plant is estimated at $280 million. Construction is scheduled to begin this year, with the facility expected to reach full operational status in 2028. While detailed roles and headcount were not disclosed, Novartis expects the site to create new positions in bioengineering, advanced manufacturing, quality and operations, contributing to economic growth in Denton and nearby communities.
The Denton plant will integrate into a national Novartis radioligand therapy manufacturing network that currently includes operating sites in New Jersey, Indiana and California, along with a recently announced facility planned for Florida. The company positions this group of plants as a coast-to-coast platform intended to provide broad capacity for radioligand therapy production.
Radioligand therapies are custom-made and time-sensitive, with each dose produced specifically for an individual patient. Because of these characteristics, proximity to treatment centers and patients is emphasized as critical to effective delivery. By deploying targeted radiation to seek out cancer cells wherever they occur in the body, this class of therapies is designed to combine precision targeting with the therapeutic power of radiation.
According to Novartis, the added capacity from the Denton facility and the broader U.S. manufacturing network is aimed at supporting access to radioligand therapies for eligible patients while maintaining the logistical reliability required for just-in-time, patient-specific production. The Denton project underscores the company's continued push to scale specialized manufacturing infrastructure as radioligand therapies gain a larger role in cancer treatment.
